• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

长链非编码RNA FOXD2-AS1作为一种竞争性内源性RNA，通过海绵吸附miR-7-5p来调节甲状腺癌中的端粒酶逆转录酶（TERT）表达。

LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer.

作者信息

Liu Xiaoli, Fu Qingfeng, Li Shijie, Liang Nan, Li Fang, Li Changlin, Sui Chengqiu, Dionigi Gianlorenzo, Sun Hui

机构信息

Division of Thyroid Surgery, Jilin Provincial Key Laboratory of Surgical Translational Medicine, China-Japan Union Hospital of Jilin University, Changchun, China.

Division for Endocrine and Minimally Invasive Surgery, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University Hospital "G. Martino", University of Messina, Messina, Italy.

出版信息

Front Endocrinol (Lausanne). 2019 Apr 8;10:207. doi: 10.3389/fendo.2019.00207. eCollection 2019.

DOI:10.3389/fendo.2019.00207
PMID:31024447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6463795/
Abstract

Long non-coding RNA FOXD2 Adjacent Opposite Strand RNA 1 (FOXD2-AS1) has been widely reported to be implicated in the progression and recurrence of several cancers. The clinical significance and functional role of FOXD2-AS1 in thyroid carcinoma remain unknown. FOXD2-AS1 expression was evaluated by analyzing thyroid cancer RNA sequencing dataset from The Cancer Genome Atlas (TCGA). and were performed to assess the biological roles of FOXD2-AS1 in thyroid cancer cells. Western blot, luciferase, immunoprecipitation (IP), and RNA immunoprecipitation (RIP) assays were used to identify the underlying miRNA and mRNA target mediating the biological roles of FOXD2-AS1 in thyroid cancer cells. FOXD2-AS1 was upregulated in thyroid carcinoma tissues and cells. High expression of FOXD2-AS1 significantly correlated with clinical stage, recurrence of thyroid carcinoma. Silencing FOXD2-AS1 inhibited cancer stem cell-like phenotypes and attenuates the anoikis resistance . Downregulating FOXD2-AS1 represses the tumorigenesis of thyroid carcinoma cells . FOXD2-AS1 acts as a competitive endogenous RNA (ceRNA) for miR-7-5p, up-regulating the expression of telomerase reverse transcriptase (TERT), which further promotes the cancer stem cells features and anoikis resistance in thyroid cancer cells. Our findings indicate that FOXD2-AS1 functions as an oncogenic regulator in the development of thyroid cancer, contributing to early recurrence of thyroid cancer.

摘要

长链非编码RNA FOXD2相邻反义链RNA 1（FOXD2-AS1）已被广泛报道与多种癌症的进展和复发有关。FOXD2-AS1在甲状腺癌中的临床意义和功能作用尚不清楚。通过分析来自癌症基因组图谱（TCGA）的甲状腺癌RNA测序数据集来评估FOXD2-AS1的表达。并进行实验以评估FOXD2-AS1在甲状腺癌细胞中的生物学作用。采用蛋白质免疫印迹法、荧光素酶报告基因检测法、免疫沉淀（IP）和RNA免疫沉淀（RIP）实验来鉴定介导FOXD2-AS1在甲状腺癌细胞中生物学作用的潜在miRNA和mRNA靶点。FOXD2-AS1在甲状腺癌组织和细胞中上调。FOXD2-AS1的高表达与甲状腺癌的临床分期、复发显著相关。沉默FOXD2-AS1可抑制癌症干细胞样表型并减弱失巢凋亡抗性。下调FOXD2-AS1可抑制甲状腺癌细胞的肿瘤发生。FOXD2-AS1作为miR-7-5p的竞争性内源性RNA（ceRNA），上调端粒酶逆转录酶（TERT）的表达，进而促进甲状腺癌细胞中的癌症干细胞特征和失巢凋亡抗性。我们的研究结果表明，FOXD2-AS1在甲状腺癌发生过程中起致癌调节作用，促进甲状腺癌的早期复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/9de8eaa58495/fendo-10-00207-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/a31d8b53024a/fendo-10-00207-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/c3e08dc180f3/fendo-10-00207-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/338c8cab11d5/fendo-10-00207-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/e45d4db9516d/fendo-10-00207-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/c0a411a701d4/fendo-10-00207-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/841ee05caa9f/fendo-10-00207-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/9de8eaa58495/fendo-10-00207-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/a31d8b53024a/fendo-10-00207-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/c3e08dc180f3/fendo-10-00207-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/338c8cab11d5/fendo-10-00207-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/e45d4db9516d/fendo-10-00207-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/c0a411a701d4/fendo-10-00207-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/841ee05caa9f/fendo-10-00207-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ba5/6463795/9de8eaa58495/fendo-10-00207-g0007.jpg

相似文献

1
LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer.长链非编码RNA FOXD2-AS1作为一种竞争性内源性RNA，通过海绵吸附miR-7-5p来调节甲状腺癌中的端粒酶逆转录酶（TERT）表达。
Front Endocrinol (Lausanne). 2019 Apr 8;10:207. doi: 10.3389/fendo.2019.00207. eCollection 2019.
2
LncRNA FOXD2-AS1 accelerates the papillary thyroid cancer progression through regulating the miR-485-5p/KLK7 axis.长链非编码RNA FOXD2-AS1通过调控miR-485-5p/KLK7轴促进甲状腺乳头状癌进展。
J Cell Biochem. 2019 May;120(5):7952-7961. doi: 10.1002/jcb.28072. Epub 2018 Nov 19.
3
Upregulation of the long non-coding RNA FOXD2-AS1 is correlated with tumor progression and metastasis in papillary thyroid cancer.长链非编码RNA FOXD2-AS1的上调与甲状腺乳头状癌的肿瘤进展和转移相关。
Am J Transl Res. 2019 Sep 15;11(9):5457-5471. eCollection 2019.
4
Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma carcinogenesis by modulating miR-363-5p/S100A1 pathway.长链非编码RNA FOXD2-AS1通过调节miR-363-5p/S100A1通路加重鼻咽癌的发生。
Gene. 2018 Mar 1;645:76-84. doi: 10.1016/j.gene.2017.12.026. Epub 2017 Dec 14.
5
Long non-coding RNA FOXD2-AS1 promotes cell proliferation, metastasis and EMT in glioma by sponging miR-506-5p.长链非编码RNA FOXD2-AS1通过吸附miR-506-5p促进胶质瘤细胞的增殖、转移和上皮-间质转化。
Open Med (Wars). 2020 Sep 30;15(1):921-931. doi: 10.1515/med-2020-0175. eCollection 2020.
6
lncRNA FOXD2-AS1 promotes hemangioma progression through the miR-324-3p/PDRG1 pathway.长链非编码RNA FOXD2-AS1通过miR-324-3p/PDRG1途径促进血管瘤进展。
Cancer Cell Int. 2020 May 24;20:189. doi: 10.1186/s12935-020-01277-w. eCollection 2020.
7
Long Noncoding RNA Promotes the Malignancy of Cervical Cancer by Sponging MicroRNA-760 and Upregulating Hepatoma-Derived Growth Factor.长链非编码RNA通过海绵吸附微小RNA-760并上调肝癌衍生生长因子促进宫颈癌的恶性发展。
Front Pharmacol. 2020 Jan 31;10:1700. doi: 10.3389/fphar.2019.01700. eCollection 2019.
8
Long noncoding RNA FOXD2-AS1 promotes glioma cell cycle progression and proliferation through the FOXD2-AS1/miR-31/CDK1 pathway.长链非编码 RNA FOXD2-AS1 通过 FOXD2-AS1/miR-31/CDK1 通路促进神经胶质瘤细胞周期进程和增殖。
J Cell Biochem. 2019 Dec;120(12):19784-19795. doi: 10.1002/jcb.29284. Epub 2019 Jul 26.
9
Long non-coding RNA FOXD2-AS1 promotes proliferation, migration and invasion of ovarian cancer cells via regulating the expression of miR-4492.长链非编码RNA FOXD2-AS1通过调控miR-4492的表达促进卵巢癌细胞的增殖、迁移和侵袭。
Exp Ther Med. 2021 Apr;21(4):307. doi: 10.3892/etm.2021.9738. Epub 2021 Feb 1.
10
Oncogenicity of lncRNA FOXD2-AS1 and its molecular mechanisms in human cancers.长链非编码 RNA FOXD2-AS1 的致癌性及其在人类癌症中的分子机制。
Pathol Res Pract. 2019 May;215(5):843-848. doi: 10.1016/j.prp.2019.01.033. Epub 2019 Jan 29.

引用本文的文献

1
LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis.LINC00162基因沉默通过调节MAPK信号通路和细胞凋亡增强索拉非尼敏感性并抑制甲状腺癌细胞进展。
Sci Rep. 2025 Aug 13;15(1):29726. doi: 10.1038/s41598-025-12805-x.
2
The role of mir-7-5p in cancer: function, prognosis, diagnosis, and therapeutic implications.miR-7-5p 在癌症中的作用：功能、预后、诊断和治疗意义。
Mol Biol Rep. 2024 Nov 25;52(1):12. doi: 10.1007/s11033-024-10107-5.
3
Long Non-coding RNA FOXD2-AS1 Silencing Inhibits Malignant Behaviors of Ovarian Cancer Cells Via miR-324-3p/SOX4 Signaling Axis.

本文引用的文献

1
Wnt5a induces and maintains prostate cancer cells dormancy in bone.Wnt5a 诱导并维持前列腺癌细胞在骨中的休眠状态。
J Exp Med. 2019 Feb 4;216(2):428-449. doi: 10.1084/jem.20180661. Epub 2018 Dec 28.
2
HOXA11 antisense long noncoding RNA (HOXA11-AS): A promising lncRNA in human cancers.HOXA11 反义长非编码 RNA（HOXA11-AS）：人类癌症中一种有前途的 lncRNA。
Cancer Med. 2018 Aug;7(8):3792-3799. doi: 10.1002/cam4.1571. Epub 2018 Jul 10.
3
Identification of differential expressed lncRNAs in human thyroid cancer by a genome-wide analyses.
长链非编码RNA FOXD2-AS1沉默通过miR-324-3p/SOX4信号轴抑制卵巢癌细胞的恶性行为。
Reprod Sci. 2025 Apr;32(4):1003-1012. doi: 10.1007/s43032-024-01719-0. Epub 2024 Oct 25.
4
Upregulation of lnc-FOXD2-AS1, CDC45, and CDK1 in patients with primary non-M3 AML is associated with a worse prognosis.原发性非M3型急性髓系白血病患者中lnc-FOXD2-AS1、CDC45和CDK1的上调与较差的预后相关。
Blood Res. 2024 Feb 19;59(1):4. doi: 10.1007/s44313-024-00002-0.
5
MiR-4492, a New Potential MicroRNA for Cancer Diagnosis and Treatment: A Mini Review.MiR-4492：一种用于癌症诊断和治疗的新型潜在微小RNA：综述
Chonnam Med J. 2024 Jan;60(1):21-26. doi: 10.4068/cmj.2024.60.1.21. Epub 2024 Jan 25.
6
Long non-coding RNAs modulate tumor microenvironment to promote metastasis: novel avenue for therapeutic intervention.长链非编码RNA通过调节肿瘤微环境促进转移：治疗干预的新途径。
Front Cell Dev Biol. 2023 Jun 13;11:1164301. doi: 10.3389/fcell.2023.1164301. eCollection 2023.
7
Identification of non-coding RNA related prognosis biomarkers based on ceRNA network in thyroid cancer.基于ceRNA网络的甲状腺癌非编码RNA相关预后生物标志物的鉴定
Front Genet. 2023 Apr 20;14:1157438. doi: 10.3389/fgene.2023.1157438. eCollection 2023.
8
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer.长非编码 RNA MFSD4A-AS1 促进甲状腺乳头状癌淋巴管生成和淋巴转移。
Endocr Relat Cancer. 2023 Feb 8;30(3). doi: 10.1530/ERC-22-0221. Print 2023 Mar 1.
9
Using ncRNAs as Tools in Cancer Diagnosis and Treatment-The Way towards Personalized Medicine to Improve Patients' Health.利用 ncRNAs 作为癌症诊断和治疗的工具——迈向改善患者健康的个体化医疗之路。
Int J Mol Sci. 2022 Aug 19;23(16):9353. doi: 10.3390/ijms23169353.
10
lncRNA FOXD2-AS1 Promotes the Retinoblastoma Cell Viability and Migration by Sponging miR-31.lncRNA FOXD2-AS1 通过海绵吸附 miR-31 促进视网膜母细胞瘤细胞的活力和迁移。
Biomed Res Int. 2022 Jun 23;2022:7723425. doi: 10.1155/2022/7723425. eCollection 2022.
通过全基因组分析鉴定人甲状腺癌中差异表达的 lncRNAs。
Cancer Med. 2018 Aug;7(8):3935-3944. doi: 10.1002/cam4.1627. Epub 2018 Jun 20.
4
miR-1266 Contributes to Pancreatic Cancer Progression and Chemoresistance by the STAT3 and NF-κB Signaling Pathways.miR-1266通过STAT3和NF-κB信号通路促进胰腺癌进展和化疗耐药。
Mol Ther Nucleic Acids. 2018 Jun 1;11:142-158. doi: 10.1016/j.omtn.2018.01.004. Epub 2018 Jan 31.
5
Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer.长链非编码 RNA FOXD2-AS1 的上调通过 EZH2 和 LSD1 表观沉默 EphB3 促进致癌作用，并预测胃癌预后不良。
Oncogene. 2018 Sep;37(36):5020-5036. doi: 10.1038/s41388-018-0308-y. Epub 2018 May 23.
6
The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1.长链非编码 RNA FOXD2-AS1 通过与 Akt 和 E2F1 的正反馈环路促进膀胱癌的进展和复发。
Cell Death Dis. 2018 Feb 14;9(2):233. doi: 10.1038/s41419-018-0275-9.
7
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.BRAF V600E/丝裂原活化蛋白激酶途径通过FOS/GABP对人类癌症中突变型端粒酶逆转录酶的调控
Nat Commun. 2018 Feb 8;9(1):579. doi: 10.1038/s41467-018-03033-1.
8
Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.鉴别微小 RNA 用于管理甲状腺乳头状癌和具有甲状腺滤泡肿瘤乳头状核特征的非侵袭性肿瘤。
Thyroid. 2018 Mar;28(3):319-327. doi: 10.1089/thy.2017.0127. Epub 2018 Mar 2.
9
RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.肿瘤细胞中 RCC2 的过表达通过调节 Rac1 的激活来改变细胞凋亡和药物敏感性。
BMC Cancer. 2018 Jan 10;18(1):67. doi: 10.1186/s12885-017-3908-y.
10
RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients.RNA测序研究确定了一种由三种新型长链非编码RNA生成的有效风险评分，用于评估甲状腺乳头状癌患者的生存情况。
Oncotarget. 2017 May 26;8(43):74139-74158. doi: 10.18632/oncotarget.18274. eCollection 2017 Sep 26.